Sunday 18 October 2026
Export AFIB’s income statement to Excel — free account
Acutus Medical, Inc.
AFIB Healthcare Medical Devices
In the quarter to December 2024, revenue grew 204.2%, EPS grew 95.9% and free cash flow grew 76.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow AFIB
| Older periods | Mar '24 | Jun '24 | Sep '24 | Dec '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.56 | 0.07 | 0.16 | 0.09 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.32) | (0.13) | (0.64) | (0.44) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.10 | 1.62 | 1.44 | 1.01 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 10.86 | |
EV/Operating CF |
(0.31) | (0.35) | (0.49) | (0.64) | |
EV/FCF |
(0.31) | (0.36) | (0.49) | (0.64) | |
Quick Ratio |
2.81 | 1.82 | 1.54 | 1.76 | |
Current Ratio |
3.48 | 2.30 | 1.85 | 2.06 | |
Net Debt/EBITDA |
(59.39) | 24.91 | 21.62 | 41.31 | |
Debt/Assets |
83.09% | 90.73% | 100.58% | 113.69% | |
Debt/Equity |
(8.61) | (6.70) | (3.14) | (2.81) | |
Asset Turnover |
0.12 | 0.18 | 0.26 | 0.49 | |
Operating CF/Net income |
10.45 | 7.63 | 0.66 | 2.89 | |
Capex/Depreciation |
(0.32) | (0.08) | (0.01) | 0.05 | |
Interest Coverage |
(0.39) | 0.20 | 0.35 | (0.20) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
92.06% | 53.91% | 44.02% | 35.80% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.57% | 3.13% | 2.43% | 0.00% | |
Graham Net Nets |
(2.11) | (13.26) | (6.42) | (8.21) | |
Graham Number |
2.64 | 2.48 | 3.34 | 1.69 | |
Earnings Yield |
(1,275.28%) | (5,651.67%) | (1,794.37%) | (545.33%) | |
Free Cash Flow Yield |
(1,208.96%) | (6,225.47%) | (1,879.05%) | (1,778.87%) | |
Revenue per Share |
0.12 | 0.14 | 0.18 | 0.24 | |
Operating CF per Share |
(0.57) | (0.23) | (0.12) | (0.14) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.57) | (0.24) | (0.12) | (0.14) | |
Cash per Share |
0.67 | 0.45 | 0.42 | 0.47 | |
Shareholders Equity per Share |
(0.14) | (0.16) | (0.35) | (0.39) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.14) | (0.16) | (0.35) | (0.39) | |
Free Cash Flow |
(17.03) | (7.01) | (3.70) | (4.02) | |
Working Capital |
24.53 | 16.08 | 12.49 | 13.14 | |
Capital Expenditures |
(0.10) | (0.04) | 0.00 | 0.04 | |
Net Current Asset Value |
(11.28) | (11.82) | (15.31) | (14.66) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.55 | 8.45 | 9.46 | 9.62 | |
Average Payables |
4.37 | 3.59 | 3.23 | 2.02 | |
Average Inventory |
10.41 | 10.44 | 9.96 | 3.03 | |
Average Assets |
78.83 | 67.88 | 58.45 | 41.30 | |
Average Common Equity |
28.22 | 19.47 | 10.70 | (6.24) |
Columns are period end dates